BOSTON, May 21, 2026 -- Aktis Oncology, Inc. (NASDAQ:AKTS) (Aktis or the Company), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large populations, including...


Dynogen developed a portfolio of therapies for gastrointestinal and genitourinary disorders. It went out of business in 2009.
Dynogen Pharmaceuticals
Waltham, MA